A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer (NCT04025879)

🧪 Interventions in This Study

• Nivolumab (BIOLOGICAL)
• Carboplatin (DRUG)
• Cisplatin (DRUG)
• Paclitaxel (DRUG)
• Pemetrexed (DRUG)
• Placebo (DRUG)
• Docetaxel (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (108 Sites)

Showing the first 25 of 108 sites.

• Local Institution - 0104 — Tampa, Florida
• Local Institution - 0040 — Atlanta, Georgia
• Local Institution - 0120 — Augusta, Georgia
• Local Institution - 0145 — Chicago, Illinois
• Local Institution - 0078 — Chicago, Illinois
• Local Institution - 0121 — Orland Park, Illinois
• Rcca Md Llc — Bethesda, Maryland
• Local Institution - 0076 — Boston, Massachusetts
• Local Institution - 0074 — Newton, Massachusetts
• Local Institution - 0086 — Traverse City, Michigan
• Local Institution - 0100 — Lebanon, New Hampshire
• Local Institution - 0055 — Cincinnati, Ohio
• Local Institution - 0102 — Cleveland, Ohio
• Local Institution - 0054 — Houston, Texas
• Local Institution - 0103 — Fredericksburg, Virginia
• Local Institution - 0043 — Buenos Aires, Buenos Aires
• Local Institution - 0032 — Ciudad Autonoma Beunos Aires, Buenos Aires
• Local Institution - 0031 — ABB, Buenos Aires F.D.
• Local Institution - 0030 — CABA,
• Local Institution - 0020 — Sydney, New South Wales
• Local Institution - 0033 — Heidelberg, Victoria
• Local Institution - 0122 — Melbourne, Victoria
• Local Institution - 0023 — North Ballarat, Victoria
• Local Institution - 0002 — Edegem,
• Local Institution - 0005 — Liège,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma, Non-Small-Cell Lung

• MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
• A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
• THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
• Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California

Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.